{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:34Z","timestamp":1793212114009,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T00:00:00Z","timestamp":1285632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic> 2010; <jats:bold>32:<\/jats:bold> 1228\u20131239<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Adalimumab induces and maintains remission in adults with Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To evaluate safety, fistula healing, quality of life and work productivity in adalimumab\u2010treated patients who failed infliximab, including primary nonresponders.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> After a \u22658\u2010week infliximab washout, patients with moderate\u2010to\u2010severe Crohn\u2019s disease received open\u2010label adalimumab as induction (160\/80\u2003mg at weeks 0\/2) and maintenance (40\u2003mg every other week) therapies. At\/after 8\u2003weeks, patients with flare\/nonresponse could receive weekly therapy. Minimum study duration was 8\u2003weeks, continuing until the commercial availability of adalimumab for Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of 673 patients enrolled, 17% were infliximab primary nonresponders and 83% were initial responders. Three percent of patients had serious infections (mainly abscesses). Complete fistula healing was achieved by 34\/88 (39%) patients with baseline fistulas. Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients, as well as the subgroup of primary nonresponders.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Blinded clinical trials have shown adalimumab to be both an effective first\u2010line therapy for anti\u2010TNF\u2010na\u00efve patients and an important treatment option for infliximab\u2010refractory or \u2010intolerant patients. This trial presents open\u2010label experience to support further the safety and effectiveness of adalimumab in patients who failed infliximab therapy, including primary nonresponders (NCT00338650).<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04466.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T04:01:31Z","timestamp":1285732891000},"page":"1228-1239","source":"Crossref","is-referenced-by-count":162,"title":["The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn\u2019s disease who failed prior infliximab therapy"],"prefix":"10.1111","volume":"32","author":[{"given":"S.","family":"Lichtiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Binion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. H.","family":"Present","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Bensimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Mulani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G.","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01140.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.168"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081950b"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081950a"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01323.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04681.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000159220.70290.41"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01561.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01779.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07285.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_21_2","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine EJ","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"issue":"3","key":"e_1_2_6_23_2","first-page":"A159","article-title":"Defining the minimally important difference for WPAI: CD Scores: What is a relevant impact on work productivity in active Crohn\u2019s disease?","volume":"56","author":"Reilly MC","year":"2007","journal-title":"Gut"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20956"},{"issue":"1","key":"e_1_2_6_26_2","article-title":"Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn\u2019s disease \u2013 first results of the EXTEND trial","volume":"5","author":"Rutgeerts P","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.069"},{"key":"e_1_2_6_28_2","first-page":"20","article-title":"Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn\u2019s disease","volume":"21","author":"Wu EQ","year":"2008","journal-title":"Manag Care Interface"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02175.x"},{"key":"e_1_2_6_30_2","volume-title":"HUMIRA\u00ae [Prescribing Information]","year":"2010"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03253.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03878.x"},{"issue":"1","key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.14309\/00000434-200809001-01069","article-title":"Adalimumab effectiveness in TNF\u2010antagonist\u2013na\u00efve Patients and in infliximab nonresponders with Crohn\u2019s disease: results from the CARE study","volume":"103","author":"Lofberg R","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-008-0107-7"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_36_2","article-title":"Dosage adjustment during long\u2010term adalimumab treatment for Crohn\u2019s disease: clinical efficacy and pharmacoeconomics","author":"Sandborn WJ","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60791-5"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00335.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20177"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04088.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.02.016"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04466.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04466.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:21:28Z","timestamp":1698783688000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04466.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,28]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04466.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04466.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,28]]}}}